Come along to our next "What's the Future...of personalised health?" panel discussion.
Personalised health is a new term being used to describe the future of healthcare, but what does this mean? Humans are all unique and the state of our health is influenced by many factors including genetics, lifestyle and environment. By examining and analysing our individual information, patterns can be identified to help determine our individual risk of developing disease, detect illness earlier and find the most effective interventions to help improve our health.
Our panel of experts will be discussing the medical move away from ‘one size fits all’ approach, the achievements and challenges of technological and scientific advances and the future of personalised health.
Dr Rachel Bearon - leads the mathematical biology research group and is responsible for User Engagement at the Liverpool Centre of Mathematics for Healthcare (LCMH). She has extensive experience of developing models bridging spatial and temporal scales to make biological predictions concerning the movement of cells within complex environments. Furthermore, she has significant expertise working directly with experimental biologists to develop novel frameworks for processing and integrating imaging data.
Rachel applies and develops mathematics to study the spatial and temporal dynamics of a wide range of biological systems across multiple scales, ranging from bacterial chemotaxis from the swimming micro-organisms phytoplankton in turbulence to modelling cell-signalling pathways and intracellular protein dynamics.
Dr Lauren Walker - an NIHR Academic Clinical Lecturer in Clinical Pharmacology & Therapeutics and general internal medicine. Her research interest is in the treatment of drug-resistant epilepsy. She qualified in medicine from the University of Liverpool, with an additional intercalated honours degree in human anatomy and cell biology.
Through her clinical lectureship Lauren continues to investigate potential biomarkers for epilepsy. She is examining patients with newly diagnosed epilepsy and whether the disulphide form of HMGB1 can predict whether or not newly-diagnosed patients with epilepsy are likely to go on to develop drug-resistance. If so, these patients could be targeted with immune-modulatory drugs. This is important as it may provide novel ways of treating patients, particularly the 30% who do not become seizure free.
Dr Andrea Jorgensen - qualified with an MSc (Distinction) in Medical Statistics at Lancaster University in 2004 (sponsored by AstraZeneca), and was awarded a PhD in Medical Statistics from the University of Liverpool in 2010. Currently a Senior Lecturer in Biostatistics at the University of Liverpool, specialising in statistical methods for pharmacogenetics and stratified medicine.
Dr Jorgensen's main research interests include statistical methods for pharmcogenetic studies and stratified medicine, randomised controlled trials in stratified medicine, meta-analysis of pharmacogenetics studies, and methodological quality of pharmacogenetic studies.